Capital Group Core Plus Income ETF (CGCP)
- Previous Close
22.56 - Open
22.49 - Bid 22.49 x 800
- Ask 22.50 x 800
- Day's Range
22.48 - 22.55 - 52 Week Range
21.07 - 23.39 - Volume
260,357 - Avg. Volume
1,084,203 - Net Assets 3.46B
- NAV 22.55
- PE Ratio (TTM) --
- Yield 5.08%
- YTD Daily Total Return 3.19%
- Beta (5Y Monthly) 0.00
- Expense Ratio (net) 0.34%
The fund will normally invest at least 80% of its assets in bonds and other debt securities, which may be represented by derivatives. It may invest in a broad range of debt securities, including corporate bonds and debt and mortgage- and other asset-backed securities issued by U.S. government-sponsored entities and federal agencies and instrumentalities that are not backed by the full faith and credit of the U.S. government. The fund is non-diversified.
Capital Group
Fund Family
Intermediate Core-Plus Bond
Fund Category
3.46B
Net Assets
2022-02-22
Inception Date
Performance Overview: CGCP
View MoreTrailing returns as of 10/28/2024. Category is Intermediate Core-Plus Bond.
People Also Watch
Related ETF News
View MoreResearch Reports: CGCP
View MoreDentsply Sirona: Suspension of Byte Aligners Throws a Wrench Into Fast-Growing Segment
Dentsply Sirona is one of the world’s largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (manufactured dental consumables and lab products) and Sirona Dental Systems (manufactured technologically-advanced dental equipment). The firm’s wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology and equipment through third-party distributors and the remaining portfolio is either sold to labs and offices through the firm’s salesforce or directly to consumers (such as Byte clear aligner).
RatingPrice TargetEdwards Lifesciences Earnings: Solid Growth Boosted by Transcatheter Mitral Valve Therapy Sales
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US
RatingPrice TargetJohnson & Johnson Earnings: Largely in Line as New Products Ready to Offset Stelara Biosimilars
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
RatingPrice TargetNew products and M&A drive 2024 growth
Johnson & Johnson is a diversified global healthcare company that develops, manufactures and markets products in two business segments: Innovative Medicine (formerly Pharmaceuticals) and MedTech.
RatingPrice Target